Specification of Retatrutide
| CAS No. | 2381089-83-2 | Molecular Weight | 4731.33 |
| Molecular Formula | C221H342N46O68 | Storage Condition | N/A |
Appearance: white freeze-dried powder
Product Description
Retatrutide is a three-target receptor agonist that is a triple agonist of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). It is mainly used for weight loss. It simultaneously activates GLP-1, GIP, and GCGR receptors, which has unique weight loss effects. LY3437943 inhibited GCGR, GIPR, and GLP-1R, with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. LY3437943 can be used in obesity research.
Product mechanism and effect
Retatrutide promotes delayed gastric emptying and appetite control by activating GLP-1 and GIP receptors, while activating glucagon receptors and increasing basal metabolism, resulting in more effective fat loss. In a phase 2 clinical trial, Retatrutide performed well in adults who were overweight and in a prediabetic state, losing more than 17.5% of their body weight.
Clinical trial data
In Phase 2 clinical trials, Retatrutide showed significant weight loss at different doses:
• 1 mg dose group : 7.2% weight loss at 24 weeks and 8.7% weight loss at 48 weeks.
• 4 mg dose group : Weight loss of 12.9% at 24 weeks and 17.1% at 48 weeks.
• 8 mg dose group : Weight loss of 17.3% at 24 weeks and 22.8% at 48 weeks.
• 12 mg dose group : 17.5% weight loss at 24 weeks and 24.2% weight loss at 48 weeks .
Suitable for population and safety
Retatrutide is suitable for adults who are overweight or obese, especially those with weight-related conditions such as type 2 diabetes, non-alcoholic fatty liver disease, etc. Retatrutide has been shown to be safe and well-tolerated at various doses in clinical trials, with no serious adverse reactions reported.
English
Nederland
